Status:
ACTIVE_NOT_RECRUITING
Iceland Screens, Treats or Prevents Multiple Myeloma
Lead Sponsor:
University of Iceland
Collaborating Sponsors:
Landspitali University Hospital
Union for International Cancer Control
Conditions:
Monoclonal Gammopathy of Undetermined Significance
Eligibility:
All Genders
40+ years
Phase:
NA
Brief Summary
This study will assess the benefits and harms of screening for monoclonal gammopathy of undetermined significance (MGUS). The overall and disease-specific mortality will be compared between screened a...
Detailed Description
Monoclonal gammopathy of undetermined significance (MGUS) is an asymptomatic premalignant stage that almost always precedes multiple myeloma (MM) and amyloidosis. It is defined by a monoclonal-(M)-pro...
Eligibility Criteria
Inclusion
- Born 1975 or earlier
- With registered address in Iceland on November 1st 2016
Exclusion
- Prior multiple myeloma
- Lymphoproliferative disease
- Amyloidosis
- M-protein \>30 g/L or involved:uninvolved serum FLC ratio \>100
- Individuals with prior history of MGUS will be offered to be randomized into either moderate or intensive clinical follow-up (arms 2 or 3).
Key Trial Info
Start Date :
September 1 2016
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2026
Estimated Enrollment :
80761 Patients enrolled
Trial Details
Trial ID
NCT03327597
Start Date
September 1 2016
End Date
September 1 2026
Last Update
September 30 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Iceland
Reykjavik, Iceland